Key Points
- Insider selling: Septerna insider Samira Shaikhly sold 6,250 shares on June 12 at an average price of $35.08, totaling about $219,250. After the sale, she held 793 shares, marking an 88.74% reduction in her position.
- Recent activity: Shaikhly also sold additional Septerna shares earlier in June and late May, including 5,935 shares on June 1 and 11,798 shares on May 26. These trades suggest a pattern of significant insider selling over a short period.
- Stock and analyst backdrop: Septerna shares were down 2.4% in the session, but the company has beaten recent earnings expectations and analysts currently rate the stock a Moderate Buy with a consensus price target of $45.78.
Septerna, Inc. (NASDAQ:SEPN - Get Free Report) insider Samira Shaikhly sold 6,250 shares of the business's stock in a transaction dated Friday, June 12th. The shares were sold at an average price of $35.08, for a total transaction of $219,250.00. Following the completion of the transaction, the insider owned 793 shares in the company, valued at $27,818.44. The trade was a 88.74% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website.
Samira Shaikhly also recently made the following trade(s):
- On Monday, June 1st, Samira Shaikhly sold 5,935 shares of Septerna stock. The shares were sold at an average price of $28.93, for a total transaction of $171,699.55.
- On Tuesday, May 26th, Samira Shaikhly sold 11,798 shares of Septerna stock. The shares were sold at an average price of $30.06, for a total transaction of $354,647.88.
Septerna Trading Down 2.4%
Shares of SEPN opened at $35.17 on Wednesday. The firm's 50-day moving average price is $27.39 and its 200-day moving average price is $26.88. The firm has a market capitalization of $1.59 billion, a price-to-earnings ratio of -43.42 and a beta of 2.39. Septerna, Inc. has a 1-year low of $9.85 and a 1-year high of $37.01.
Septerna (NASDAQ:SEPN - Get Free Report) last announced its earnings results on Tuesday, May 12th. The company reported ($0.19) earnings per share for the quarter, beating analysts' consensus estimates of ($0.42) by $0.23. The firm had revenue of $26.52 million for the quarter, compared to analyst estimates of $16.98 million. Septerna had a negative net margin of 49.88% and a negative return on equity of 12.72%. On average, research analysts forecast that Septerna, Inc. will post -1.57 EPS for the current fiscal year.
Institutional Investors Weigh In On Septerna
Hedge funds have recently bought and sold shares of the business. Avoro Capital Advisors LLC boosted its stake in Septerna by 8.1% during the third quarter. Avoro Capital Advisors LLC now owns 1,337,500 shares of the company's stock worth $25,158,000 after acquiring an additional 100,000 shares in the last quarter. Balyasny Asset Management L.P. bought a new stake in Septerna during the fourth quarter worth about $100,000. BNP Paribas Financial Markets boosted its stake in Septerna by 88.0% during the third quarter. BNP Paribas Financial Markets now owns 4,155 shares of the company's stock worth $78,000 after acquiring an additional 1,945 shares in the last quarter. Caitong International Asset Management Co. Ltd bought a new stake in Septerna during the fourth quarter worth about $53,000. Finally, Russell Investments Group Ltd. bought a new stake in Septerna during the third quarter worth about $36,000.
Analyst Ratings Changes
A number of equities research analysts have recently weighed in on SEPN shares. Stifel Nicolaus started coverage on shares of Septerna in a research note on Friday, May 1st. They set a "buy" rating and a $43.00 target price on the stock. Zacks Research raised shares of Septerna from a "strong sell" rating to a "hold" rating in a research note on Tuesday, February 24th. Truist Financial lifted their target price on shares of Septerna from $34.00 to $35.00 and gave the company a "buy" rating in a research note on Wednesday, March 11th. Wells Fargo & Company lifted their target price on shares of Septerna from $28.00 to $48.00 and gave the company an "overweight" rating in a research note on Tuesday, March 3rd. Finally, Cantor Fitzgerald reaffirmed an "overweight" rating and set a $60.00 target price on shares of Septerna in a research note on Tuesday, March 10th. Two investment analysts have rated the stock with a Strong Buy rating, seven have assigned a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, Septerna presently has a consensus rating of "Moderate Buy" and a consensus price target of $45.78.
View Our Latest Stock Analysis on Septerna
Septerna Company Profile
(
Get Free Report)
We are a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) oral small molecule drug discovery powered by our proprietary Native Complex Platform™. Our industrial-scale platform aims to unlock the full potential of GPCR therapies and has led to the discovery and development of our deep pipeline of product candidates focused initially on treating patients in three therapeutic areas: endocrinology, immunology and inflammation, and metabolic diseases. GPCRs are the largest and most diverse family of cell membrane receptors and regulate physiological processes in nearly every organ system of the human body.
See Also
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
